|
Girls, n (%)
|
132 (59.7)
|
61 (69.3)
|
71 (53.4)
|
|
Age at onset, median (IQR)
|
6.1 (8.1, 2.3–10.4)
|
6.8 (8.4, 0.7–14.2)
|
5.2 (7.2, 0.9–14.7)
|
|
Age at visit by paediatric rheumatologists at the hospital, median (IQR)
|
12.7 (5.3, 9.4–14.7)
|
13.1 (3.3, 5.2–16.1)
|
11.7 (6.5, 4.8–16.5)
|
|
Disease duration, median (IQR)
|
4.6 (5.7, 2.6–8.3)
|
4.6 (6.0, 0.2–14.2)
|
4.6 (5.5, 0.2–14.7)
|
|
JIA categories, n (%)
|
|
Oligoarthritis persistent
|
77 (34.8)
|
27 (30.7)
|
50 (37.6)
|
|
Oligoarthritis extended
|
21 (9.5)
|
11 (12.5)
|
10 (7.5)
|
|
Systemic arthritis
|
7 (3.2)
|
2 (2.3)
|
5 (3.8)
|
|
RF negative polyarthritis
|
49 (22.2)
|
17 (19.3)
|
32 (24.1)
|
|
RF positive polyarthritis
|
4 (1.8)
|
2 (2.3)
|
2 (1.5)
|
|
Psoriatic arthritis
|
9 (4.1)
|
6 (6.8)
|
3 (2.3)
|
|
Enthesitis-related arthritis
|
23 (10.4)
|
9 (10.2)
|
14 (10.5)
|
|
Undifferentiated JIA
|
31 (14.0)
|
14 (15.9)
|
17 (12.8)
|
|
Ongoing medication, n (%)
|
|
No DMARDs
|
75 (33.9)
|
26 (11.8)
|
49 (22.2)
|
|
sDMARDs*
|
60 (27.1)
|
23 (10.4)
|
37 (16.7)
|
|
bDMARDs**
|
86 (38.9)
|
39 (17.6)
|
47 (21.3)
|
